Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Atomic Force Microscope Shows Antibodies Can Prevent Fibrils
26 January 2004. A nifty instrument for mapping the 3-D shape of macromolecular surfaces, the atomic force microscope (AFM) over the last five years has become an established method of measuring how environmental conditions affect Aβ fibril formation as well as oligomerization of other proteins implicated in neurodegeneration (see ARF related news story, selected citations in right margin). Of a current spate of studies using this desktop machine (see Liu et al, 2004, Moreno-Herrero et al., 2004, Gibson et al., 2004), one published in the January 23 Journal of Molecular Biology has employed it to characterize how Aβ antibodies interfere with fibrillization. One of these antibodies is thought to improve memory performance in a mouse model by attacking soluble Ab oligomers.

Justin Legleiter, working with Tomasz Kowalewski at Carnegie Mellon University in Pittsburgh and colleagues elsewhere, incubated Aβ42 with monoclonal antibodies to both the N-terminal end and the central domain of the peptide. They then used the AFM to measure the amount and length of fibrils formed. The m266 antibody is being investigated in passive vaccination paradigms (see ARF related news story; also see DeMattos et al. in ARF related news story), and the m3D6 has been studied with multiphoton microscopy for its ability to clear amyloid deposits in brain, (see Bacskai et al., 2002. For further information on these and other Ab antibodies, see Alzforum antibody directory).

The researchers found that the N-terminal antibody (m3D6) slowed down formation of Aβ fibrils, while the central domain antibody (m266.2) almost completely prevented this process. After incubating the proteins for five days, about three fibrils per square micrometer were detected in the absence of antibody. This density shrank to less than 0.5 fibrils when m3D6 was in the mix, and to almost zero in the presence of m266.2. A similar trend was apparent when Legleiter and colleagues examined fibril length. In the absence of antibody, the longest fibril recorded was 800 nanometers. m3D6 decreased fibril length to about 400, m266.2 to 50 nanometers.

The authors conclude that the differences are best explained by the antigen specificities of the antibodies, writing that m266.2 is better at preventing aggregation because it binds close to the hydrophobic core of the peptide, which is most involved in fibril formation (see ARF related news story). However, the relative affinities of the two antibodies are not discussed.

As for the atomic force microscope itself, its capacity to measure the contours and lengths of single Aβ fibrils indicates that it could be a useful tool for estimating the efficacy of potential fibril busters.—Tom Fagan.

Reference:
Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. Journal of Molecular Biology 23 January 2004;335:997-1006. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad